Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors-Reference-Cited by-同舟云学术

Body Composition and Clinical Outcomes in Esophageal Cancer Patients Treated with Immune Checkpoint Inhibitors

Published:2024-02-29 Issue:6 Volume:31 Page:3839-3849
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Kosumi Keisuke,Baba Yoshifumi,Hara Yoshihiro,Wang Haolin,Nomoto Daichi,Toihata Tasuku,Ohuchi Mayuko,Harada Kazuto,Eto Kojiro,Ogawa Katsuhiro,Ishimoto Takatsugu,Iwatsuki Masaaki,Iwagami Shiro,Miyamoto Yuji,Yoshida Naoya,Baba Hideo

Funder

Uehara Memorial Foundation

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1245/s10434-024-15093-3.pdf

Reference52 articles.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

2. Zheng X, Song X, Shao Y, et al. Prognostic role of tumor-infiltrating lymphocytes in esophagus cancer: a meta-analysis. Cell Physiol Biochem. 2018;45(2):720–32.

3. Gao TT, Shan JH, Yang YX, et al. Comparative efficacy and safety of immunotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma: a systematic review and network Meta-analysis. BMC Cancer. 2022;22(1):992.

4. Kadono T, Yamamoto S, Kato K. Current perspectives of the Japanese esophageal oncology group on the development of immunotherapy for esophageal cancer. Jpn J Clin Oncol. 2022;52:1089.

5. Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506–17.